The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Arashiro Toshiaki, Ryukyu-Okinawa Rekishi Jinbutsuden, Okinawajijishuppan, 2006 p66 ISBN 978-4-903042-04-6 "Reevaluation of surgical achievements by Tokumei Takamine". Matsuki A. Masui. November 2000; 49(11):1285-9. Japanese. "The secret anesthetic used in the repair of a hare-lip performed by Tokumei Takamine in Ryukyu". Matsuki A. Nippon Ishigaku Zasshi. October 1985 31(4):463-89. Japanese.
== External links == "Formylpeptide Receptors: FPRL1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== History == The company was founded on September 7, 1960, in Karlsruhe, Germany as Bruker-Physik AG by five people, one of them being Günther Laukien, who was a professor at the University of Karlsruhe at the time. The name Bruker originates from co-founder Emil Bruker, as Günther Laukien himself was formally not allowed to commercialize his research whilst being a professor. Bruker produced Nuclear Magnetic Resonance Spectroscopy (NMR) and EMR spectroscopy equipment then. In the early 1960s, the company had around 60 employees and was growing rapidly. One of the early success products was the HFX 90 NMR spectroscopy system, with three independent channels and which was also the first NMR system using only semiconductor transistors. In 1969, Bruker launched the first commercial Fourier transform NMR spectroscopy system (FT-NMR) and in the 1970s the company was the first to commercialize a superconducting FT-NMR. Later, the company would expand their product range with MRI, FTIR and FT-Raman spectrometers and with mass spectrometers. In 1968, Bruker shipped NMR systems to Yale University in Connecticut. After that, demand from the US grew, so Bruker opened an office in Elmsford, New York which marked the start of their US activities. In 2008 after a corporate reorganization lasting 8 years, all divisions were merged in a unified Bruker Corporation. Günther Laukien died in 1997; one of his four sons Frank Laukien, is currently the CEO of Bruker. Another son, Jörg C. Laukien, also works for the company. Another son, Dirk D. Laukien, is a former company executive.
Sources: en.wikipedia.org
An alternative latex method sometimes used in China in the past is to cut off the poppy heads, run a large needle through them, and collect the dried latex 24 to 48 hours later. In India, opium harvested by licensed poppy farmers is dehydrated to uniform levels of hydration at government processing centers and then sold to pharmaceutical companies that extract morphine from the opium. However, in Turkey and Tasmania, morphine is obtained by harvesting and processing the fully mature dry seed pods with attached stalks, called poppy straw. In Turkey, a water extraction process is used, while in Tasmania, a solvent extraction process is used. Opium poppy contains at least 50 different alkaloids, but most of them are of low concentration. Morphine is the principal alkaloid in raw opium and constitutes roughly 8–19% of opium by dry weight (depending on growing conditions). Some purpose-developed strains of poppy now produce opium that is up to 26% morphine by weight. A rough rule of thumb to determine the morphine content of pulverised dried poppy straw is to divide the percentage expected for the strain or crop via the latex method by eight or an empirically determined factor, which is often in the range of 5 to 15. The Norman strain of P. somniferum, also developed in Tasmania, produces as little as 0.04% morphine but with much higher amounts of thebaine and oripavine, which can be used to synthesise semi-synthetic opioids as well as other drugs like stimulants, emetics, opioid antagonists, anticholinergics, and smooth-muscle agents.
== Therapeutic touch and nursing education == Sokal, in 2006, reported generally accepted estimates of over 80 colleges and universities spread over 70 countries where therapeutic touch is taught, as well as some 80 hospitals in North America where it is practiced. He added that "these figures should be taken with a grain of salt, since both advocates and detractors [...] have an interest in exaggerating its incidence". Owen Hammer and James Underdown of the Independent Investigations Group examined nursing standards in California, where the California Board of Registered Nursing can award registered nurses taking classes in therapeutic touch with continuing education units required for licensure renewal. In 2006, Hammer and Underdown presented the board with the scientific evidence refuting the validity of therapeutic touch as a legitimate treatment, but the board did not change its policy.
The president had only joined the cry of "Down with the Republicans!" in Montalembert in the hope of effecting a revision of the constitution without having recourse to a coup d'état. His concessions only increased the boldness of the monarchists, who had only accepted Louis-Napoléon as president in opposition to the Republic and as a step in the direction of the monarchy. A conflict was now inevitable between his personal policy and the majority of the Chamber, who were divided into legitimists and Orléanists in spite of the death of Louis-Philippe in August 1850. Louis-Napoléon exploited their projects for a restoration of the monarchy, which he knew to be unpopular in the country, and which gave him the opportunity of furthering his own personal ambitions. From 8 August to 12 November 1850 he went about France stating the case for a revision of the constitution in speeches which he varied according to each place; he held reviews, at which cries of "Vive Napoléon!" showed that the army was with him; he superseded General Changarnier, on whose arms the parliament relied for the projected monarchical coup d'état; he replaced his Orléanist ministry with obscure men devoted to his own cause, such as Morny, Fleury and Persigny, and gathered round him officers of the African army, broken men like General Saint-Arnaud; in fact he practically declared open war.
His wife also says that Edwards is receiving in-patient hospital care after an episode of depression following the publication of the allegations. Following an investigation into the allegations, the Metropolitan Police releases a statement to say detectives have determined no criminal offence has been committed. The Bank of England says that rising interest rates mean that mortgages for at least one million borrowers will rise by an average of £500 a month by the end of 2023. The 2.6 GW Hornsea Project 4 is approved by the government, becoming the second-largest UK wind farm to receive planning consent, following Hornsea Project Three. 13 July The longest doctor's strike in NHS history begins, as junior doctors begin a five-day walkout over pay. The government offers more than a million public sector workers in England and Wales a pay rise worth an average of 6%. The offer sees police and prison officers in England and Wales offered 7%, with teachers in England offered 6.5%, and junior doctors in England offered 6%. A report published by the Intelligence and Security Committee of Parliament says the UK failed to develop an effective strategy for dealing with threats to its national security by China, which has allowed Chinese intelligence to aggressively target the UK. 14 July Data published by the Office for National Statistics indicates one in 20 people surveyed reported running out of food, and being unable to afford to buy more because of rising food prices.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.